Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Sellas Life Sciences Group
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CellCentric Ltd.
BeOne Medicines
University of Florida
Kura Oncology, Inc.
Fred Hutchinson Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
Biotroy Therapeutics
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Indapta Therapeutics, INC.
Thomas Jefferson University
M.D. Anderson Cancer Center
Takeda
Shenzhen TargetRx, Inc.
Bellicum Pharmaceuticals
Fate Therapeutics
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Molecular Templates, Inc.
Bellicum Pharmaceuticals
University of Michigan Rogel Cancer Center
Gamida Cell ltd
Novartis
Gamida Cell ltd
Chinese PLA General Hospital
Incyte Corporation
Chinese PLA General Hospital
Ciusss de L'Est de l'Île de Montréal
Masonic Cancer Center, University of Minnesota
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Chinese PLA General Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chinese PLA General Hospital
Gilead Sciences
Baylor College of Medicine
Accenture
Duke University
M.D. Anderson Cancer Center